# US 9,006,288 B2 · Composition and method for treatment of diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,006,288 B2
- Document ID: US9006288B2
- Status: Granted
- Kind: B2
- Application number: 14/020,477
- Filed: 2013-09-06
- Published: 2014-01-09
- Granted: 2015-04-14
- Earliest claimed: 2009-01-12
- Assignees: BioKier, Inc.
- Applicants: BioKier, Inc.
- Inventors: Jerzy Ryszard Szewczyk
- Web page: https://patentgrep.com/patent/US9006288B2

## CPC

- A61K 9/0087: {Galenical forms not covered by A61K9/02 - A61K9/7023}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/195: having an amino group
- A61K 9/0031: {Rectum, anus}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.

## Claims

### Claim 1

A method of treating type I diabetes, type II diabetes, hypertriglyceridemia, obesity, appetite control, metabolic syndrome, polycystic ovary syndrome in an individual affected by a decrease or lack of release of a gut hormone secreted from L cells comprising stimulating the production of an L cell secreted gut hormone in the colon of the individual, the method comprising:
a) selecting an omega-3 polyunsaturated fatty acid composition causing gut hormone secretion from L-cells, the composition formulated to release in a colon targeted delivery system or in a rectal release system; and
b) administering sufficient composition to the individual colon or rectum sufficient to cause a release of gut hormones from the L-cell in the colon of the individual sufficient to achieve the desired result.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the colon targeted delivery system is a matrix within matrix delivery system.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the colon targeted delivery system is a controlled release formulation of a hydrophilic first matrix comprising a lipophilic phase and an amphiphilic phase wherein the lipophilic phase and the amphiphilic phase are in a second matrix together and said second matrix is dispersed throughout the hydrophilic first matrix wherein the agent is at least partially incorporated into the amphiphilic phase.